Buyse, Marc <br/><br/>
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.  [electronic resource] 

 -  Haematologica  Aug 2011 
 - 1106-12 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2010.039131  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers<br/>Disease-Free Survival<br/>Histamine--therapeutic use<br/>Humans<br/>Immunotherapy<br/>Interleukin-2--administration & dosage<br/>Kaplan-Meier Estimate<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Maintenance Chemotherapy<br/>Remission Induction<br/>Time Factors<br/>Treatment Outcome